KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc., announces publication of data for two more tests, HART AS and HART AKI, in its expanding pipeline of multi-protein, AI-driven tests for cardiovascular disease and related conditions.
The HART AS data was presented at the 2018 American College of Cardiology Scientific Sessions and was recently published in Open Heart, indicating it accurately diagnoses symptomatic Aortic Stenosis (AS)—a condition with a 50 percent death rate within one year when left untreated. HART AS could lead to earlier diagnosis and treatment of many more patients with AS. AS is the most common valvular heart disease in the Western world, present in more than 20 percent of older adults. Researchers believe the data could lead to the HART AS test as a more widely-available, less expensive, and more accurate test than echocardiography, otherwise known as ultrasound of the heart.
The HART AKI data was presented at the 2018 American Heart Association Scientific Sessions and was published this month in Clinical Cardiology, indicating high accuracy for predicting Acute Kidney Injury (AKI) risk. AKI following coronary angiographic procedures is associated with significant morbidity and death. The number of coronary angiographic procedures resulting in AKI rose almost 3‐fold from 2001 to 2011. Researchers believe the data is of great value as it could alter patient management and reduce the alarming incidence of AKI.
Principal investigator James L. Januzzi, MD, practicing cardiologist at Massachusetts General Hospital (MGH) and Professor of Medicine at Harvard Medical School, said, “There is a huge unmet need to accurately diagnose and treat the presence of aortic valve stenosis and to assess the risk of acute kidney injury due to cardiac procedures. Though single biomarker tests have helped to refine diagnosis and prognosis, it is clear the future will be with a multiple biomarker approach supported by cutting-edge machine learning. Additionally, we believe such tests could also play an important role in identifying high risk patients for enrollment in clinical trials, thereby saving time and lowering overall trial costs.”
“We are pleased to now have five peer-reviewed publications validating the impressive accuracy of our HART tests, which have the potential to improve treatment for millions of cardiovascular patients, as well as improving drug development, testing drug efficacy, and decreasing clinical trial expenses for pharmaceutical companies,” said Rhonda Rhyne, Prevencio’s Chief Executive Officer. “We are very thankful for our ongoing collaboration with Dr. Januzzi, MGH researchers, Myriad RBM, and our investors.”
Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease. Employing this novel approach, the company has developed six blood tests to-date that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
These tests are:
- HART CAD™ – obstructive coronary artery disease diagnosis
- HART CVE™ – 1-year risk of heart attack, stroke or cardiac death
- HART PAD™ – peripheral artery disease diagnosis
- HART AS™ – aortic valve stenosis diagnosis
- HART AMP™ – risk of amputation
- HART AKI™ – risk of acute kidney injury
HART test results have been presented at leading cardiovascular meetings—(European Society of Cardiology Congress Scientific Sessions – 2016 & 2018, American College of Cardiology Scientific Sessions – 2017 & 2018, American Heart Association Scientific Sessions – 2017 & 2018, and American Diabetes Association Scientific Sessions – 2018) and published in top-tier cardiology journals—(Journal of American College of Cardiology – March 2017, American Journal of Cardiology – July 2017, Open Heart – November 2018 and Clinical Cardiology – June 2018 & January 2019).
About Prevencio, Inc.:
Prevencio's value proposition is
"Preventing the Preventable” — That is, preventing unnecessary
procedures and related side effects, as well as improving patient
outcomes and clinical trials through more accurate blood tests for
Cardiovascular Disease conditions. Prevencio utilizes Machine Learning
(Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary
Algorithms to deliver cardiovascular diagnostic & prognostic tests that
are significantly more accurate than standard-of-care stress tests,
individual biomarkers, genetic markers and clinical risk scores. The
company is headquartered in Kirkland, Washington. For additional
information, visit www.PrevencioMed.com.
Prevencio—Preventing the Preventable.™
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, size, potential, and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on HART technology and various uncertainties characteristic of development-stage companies. The Company does not undertake to update the disclosures contained in this press release.
